Glucose-induced CRL4 COP1 -p53 axis amplifies glycometabolism to drive tumorigenesis

Yang Su,Yifan Luo,Peitao Zhang,Hong Lin,Weijie Pu,Hongyun Zhang,Huifang Wang,Yi Hao,Yihang Xiao,Xiaozhe Zhang,Xiayun Wei,Siyue Nie,Keren Zhang,Qiuyu Fu,Hao Chen,Niu Huang,Yan Ren,Mingxuan Wu,Billy Kwok Chong Chow,Xing Chen,Wenfei Jin,Fengchao Wang,Li Zhao,Feng Rao

DOI: https://doi.org/10.1016/j.molcel.2023.06.010

IF: 16

2023-06-30

Molecular Cell

Abstract:Summary The diabetes-cancer association remains underexplained. Here, we describe a glucose-signaling axis that reinforces glucose uptake and glycolysis to consolidate the Warburg effect and overcome tumor suppression. Specifically, glucose-dependent CK2 O-GlcNAcylation impedes its phosphorylation of CSN2 , a modification required for the deneddylase CSN to sequester Cullin RING ligase 4 (CRL4). Glucose, therefore, elicits CSN-CRL4 dissociation to assemble the CRL4 COP1 E3 ligase, which targets p53 to derepress glycolytic enzymes . A genetic or pharmacologic disruption of the O-GlcNAc-CK2-CSN2-CRL4 COP1 axis abrogates glucose-induced p53 degradation and cancer cell proliferation. Diet-induced overnutrition upregulates the CRL4 COP1 -p53 axis to promote PyMT-induced mammary tumorigenesis in wild type but not in mammary-gland-specific p53 knockout mice. These effects of overnutrition are reversed by P28, an investigational peptide inhibitor of COP1-p53 interaction. Thus, glycometabolism self-amplifies via a glucose-induced post-translational modification cascade culminating in CRL4 COP1 -mediated p53 degradation. Such mutation-independent p53 checkpoint bypass may represent the carcinogenic origin and targetable vulnerability of hyperglycemia-driven cancer.

cell biology,biochemistry & molecular biology

What problem does this paper attempt to address?

The paper attempts to address the mechanism linking diabetes and cancer, particularly how hyperglycemia promotes tumorigenesis and progression by regulating glucose metabolism. Specifically, the authors investigated how the glucose signaling axis consolidates the Warburg effect by enhancing glucose uptake and glycolysis, and overcoming tumor suppression. The main finding of the paper is that glucose-induced CRL4COP1-p53 axis leads to the degradation of p53 through a series of post-translational modifications, thereby amplifying glucose metabolism and driving tumorigenesis.

### Main Issues:
1. **Mechanism linking diabetes and cancer**:
- Diabetes (especially type 1 and type 2 diabetes) increases the risk of various cancers.
- Hyperglycemia is a common feature of diabetes and is associated with cancer risk, but the specific molecular mechanisms remain unclear.

2. **How glucose affects glucose metabolism and tumorigenesis**:
- How the glucose signaling axis enhances glucose uptake and glycolysis, consolidating the Warburg effect.
- How glucose affects the phosphorylation of CSN2 through post-translational modifications (such as O-GlcNAcylation), leading to the assembly of the CRL4COP1 complex and the degradation of p53.

3. **Role of p53 in glucose metabolism and tumor suppression**:
- p53 is not only a checkpoint for cellular integrity but also a major metabolic suppressor, inhibiting glucose catabolism and anabolism through transcription.
- How glucose promotes tumorigenesis by degrading p53, thereby lifting its inhibition on glycolysis.

### Main Findings of the Paper:
- **Glucose-induced post-translational modifications**:
- Glucose-dependent CK2 O-GlcNAcylation hinders the phosphorylation of CSN2, leading to the dissociation of the CSN-CRL4 complex.
- Glucose-induced CSN-CRL4 dissociation promotes the assembly of the CRL4COP1 E3 ligase, which targets p53 for degradation.

- **Degradation of p53 and tumorigenesis**:
- Glucose-induced p53 degradation amplifies glucose metabolism through transcriptional programming, thereby driving tumorigenesis.
- Diet-induced overnutrition promotes PyMT-induced mammary tumorigenesis by activating the CRL4COP1-p53 axis.

- **Potential therapeutic targets**:
- Peptide inhibitors of the COP1-p53 interaction, such as P28, can reverse hyperglycemia-induced p53 degradation and cancer cell proliferation.
- This mutation-independent p53 checkpoint bypass may be the oncogenic origin and targetable vulnerability of hyperglycemia-driven cancer.

### Conclusion:
The paper reveals the mechanism by which glucose regulates glucose metabolism and tumorigenesis through the CRL4COP1-p53 axis, providing new insights into the link between diabetes and cancer, and offering potential targets for developing therapies against hyperglycemia-driven cancer.